Treatment of advanced prostate cancer has improved rapidly in the past two decades with the introduction of many new therapeutics including several entirely new therapeutic classes. Whereas androgen deprivation therapy was previously the first and only line of treatment available, modern therapy also routinely employs second-generation anti-androgens, chemotherapy, immunotherapy, radiopharmaceuticals, bone modifying agents, and poly(ADP-ribose) polymerase (PARP) inhibitors, with a resulting substantial increase in patient survival.  This journal-based accredited continuing education (CME) activity focuses on summarizing the current treatment landscape for advanced prostate cancer, with a particular focus on hormone-refractory prostate cancer. 

REGISTRATION FEES:

This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0. 

Healthcare providers ($0.00)

Industry employees ($0.00)

If you are a healthcare provider involved in patient care and you are not employed by the Industry, register for free!

ACCREDITATION

1.00 AMA PRA Category 1 Credit™

The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.